Jack L. Wyszomierski Sells 8,768 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $38.69 on Friday. The firm has a market cap of $10.83 billion, a price-to-earnings ratio of 21.86, a P/E/G ratio of 1.13 and a beta of 0.53. The firm has a fifty day moving average price of $34.53 and a 200 day moving average price of $31.62. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $38.72.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on EXEL. Barclays boosted their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $36.00 to $40.00 in a report on Friday, December 20th. Guggenheim reissued a “buy” rating and set a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Finally, Wells Fargo & Company downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective on the stock. in a research note on Monday, February 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.24.

Institutional Trading of Exelixis

A number of large investors have recently added to or reduced their stakes in the company. Seizert Capital Partners LLC boosted its position in shares of Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after acquiring an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares in the last quarter. Tri Ri Asset Management Corp bought a new position in Exelixis during the third quarter valued at $4,396,000. CWA Asset Management Group LLC purchased a new position in shares of Exelixis in the 3rd quarter worth $577,000. Finally, Blue Trust Inc. increased its holdings in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after buying an additional 8,208 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.